Saturday, Jun 10, 2023

Newly-launched U.S. drugs head toward record-high prices in 2022

Newly-launched U.S. drugs head toward record-high prices in 2022

Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing power even as Congress moves to cut the $500 billion-plus annual bill for prescription drugs in the United States.

At the same time, some pharmaceutical manufacturers are disclosing less information about the pricing of those treatments, which have come under greater scrutiny in recent years, Reuters found.

"In the U.S. we allow drug manufacturers to freely set prices for all brand-name drugs," Dr. Aaron Kesselheim, professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, told Reuters.

The median annual price of 13 novel drugs approved for chronic conditions by the U.S. Food and Drug Administration so far this year is $257,000, Reuters found.

They were in good company: seven other newly-launched drugs were priced above $200,000. Three other drugs launched in 2022 are used only intermittently and were not included in the calculation.

Last year, the median annual price rose to $180,000 for the 30 drugs first marketed through mid-July 2021, according to a study published recently in JAMA.

While the Reuters tally does not completely replicate the work of that study, it shows that the direction of new drug prices continues to be on the rise.

The JAMA study also excluded drugs that are used intermittently. It included an adjustment for the fact that drugs for very rare diseases have higher prices, which Reuters did not.

The pharmaceutical industry says that prices for new drugs, many of which now treat rare diseases for which there are no therapies, reflect their value to patients, including the ability to prevent costly emergency room visits and hospital stays.

Drugmakers also stress that they do not determine what U.S. patients end up paying for the medicines.

"Each person’s individual (health) insurer and plan will determine the out-of-pocket costs," Eli Lilly & Co said in response to a question about the $12,700 annual price of its new diabetes drug Mounjaro, adding that the company offers savings cards to reduce those costs to as little as $25 a month.


At the same time, drug price information has become harder to confirm. Reuters requested price data from all 15 of the companies that launched new drugs this year.

Six of the manufacturers either did not respond to a request for price details or initially provided only partial information, such as a "per vial" cost, rather than an annual cost based on average patient use, as they had in the past.

Sanofi (SASY.PA) said its new drug Enjaymo, used to treat a rare type of anemia, was priced at $1,800 per vial. When pressed further, the French healthcare group clarified that the typical annual price is $280,800.

Immunocore (IMCR.O) initially disclosed only a "per vial" price for melanoma drug Kimmtrak, and Dermavant Sciences gave only a "per tube" price for its new psoriasis cream. Bristol Myers Squibb (BMY.N) quoted a "per infusion" price for cancer treatment Opdualag. All three eventually provided annual prices.

CTI BioPharma (CTIC.O) referred Reuters to a third-party database, but later gave a monthly price for its rare anemia treatment Vonjo. Mycovia Pharmaceuticals said that "as a private company" it would not provide information on the price of its antifungal drug Vivjoa.

Dr. Ameet Sarwaptwari, a Harvard University professor who specializes in healthcare law, said such incomplete disclosure could be “an attempt to distract” from high annual costs.

Some drugmakers, in response, say treatment costs can vary depending on patient weight and other factors, complicating the estimation of prices for an average patient.

Congress last week passed the landmark $430 billion Inflation Reduction Act that includes a cap on annual drug price increases and allows the Medicare health program for seniors to negotiate prices for up to 20 of the drugs on which it spends the most.

The bill, however, does not limit what drugmakers can charge for new drugs. Some industry experts say that could leave manufacturers even more reliant on higher launch prices.

"The industry will turn to new drugs to try to use the lever that remains uncontrolled," said Daniel Ollendorf, of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center.

The JAMA-published study on drug prices showed that between 2008 and 2021, U.S. drug launch prices grew 20% annually.

On a net basis, which accounts for volume-based rebates and other discounts that health insurers negotiate with drugmakers, prices for new drugs rose by 11% a year, according to the study led by researchers from the Boston-based Program on Regulation, Therapeutics, and Law and from Brigham and Women’s Hospital.

Reuters did not calculate a comparable rise for 2022 as such discounts are not made public.

Discounts and rebates are often demanded by payers for new drugs once competing treatments become available. As patents expire, lower-cost generics also mitigate prescription drug price inflation, which in the 12 months through July has grown by 2.8%, according to the Bureau of Labor Statistics.

"The vast majority of drugs that Americans use are generics," said Rena Conti, associate professor at Boston University's business school. Drugs for diseases with few treatment options command the highest prices, she said.

AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.

Oh ya 297 days ago
On the bright side this might cure some of the millions of people who are too lazy to change there unhealthy lifestyle and rely on drugs to keep them alive as they eat their McRot burgers and such


Related Articles

US and European Intelligence Agencies Uncover Evidence of Ukrainian Role in Terror Attack on Nord Stream Pipeline
Nvidia Joins Tech Giants as First Chipmaker to Reach $1 Trillion Valuation
Drone Attack on Moscow's Wealthiest Neighborhoods Suspected to be Launched by Ukraine
UK Prime Minister Rishi Sunak to Hold Power Talks with President Biden in Washington
AI ‘extinction’ should be same priority as nuclear war – experts
Prominent Hacker Forum RaidForums Suffers Substantial Data Breach
Nvidia CEO Huang says firms, individuals without AI expertise will be left behind
WPP Revolutionizes Advertising with NVIDIA's AI Powerhouse
Two US Employees Fired For Chasing Robbers Out Of Store As They Broke ''Company Policy''
If you donated to BLM, you got played
Pfizer, the EU, and disappearing ink - Smoke, Mirrors, and the Billion-Dose Pfizer Vaccine Deal: EU's 'Open Secret
Actor Tom Hanks told Harvard University graduates to be superheroes in their defense of truth and American ideals, and to resist those who twist the truth for their own gain
The Sussexes' Royal Rebound: Could Harry and Meghan Markle Return to the UK?
A provocative study suggests: Left-Wing Extremism and its Unsettling Connection to Psychopathy and Narcissism
France Arrests 10 on Suspicion of Failing to Respond in Time to Migrant Drowning
Neuralink Receives FDA Approval for First-in-Human Clinical Study
Saudi Arabia and Canada Restore Diplomatic Relations
Bernard Arnault Loses $11.2 Billion in One Day as Investors Fear Slowdown in US Growth Will Reduce Demand for Luxury Products
Russian’s Wagner Group leader: “I am not a chef, I am a butcher. Russia is in danger of a revolution like in 1917.”
TikTok Sues Montana Over Law Banning the App
Ron DeSantis Jumps Into 2024 Presidential Race, Setting Up Showdown With Trump
Last Walmart in North Portland Closing Down
Florida's DeSantis seeks to disqualify judge in Disney case
Talks between US House Republicans and President Biden's Democratic administration on raising the federal government's $31.4tn debt ceiling have paused
Disney has canceled plans to build a new campus in Florida worth almost $1 billion
Biden Administration Eyeing High-Profile Visits to China: The Biden Administration is heating things up by looking into setting up a series of top-level visits to Beijing by top officials in the coming months
New evidence in special counsel probe may undercut Trump’s claim documents he took were automatically declassified
A French court of appeals confirmed former President Nicolas Sarkozy's three-year jail term for corruption and influence peddling
Debt Ceiling Crises Have Unleashed Political Chaos
Weibao Wang, a former software engineer at Apple, was charged with stealing trade secrets related to autonomous systems, including self-driving cars
Mobile phone giant Vodafone to cut 11,000 jobs globally over three years as new boss says its performance not good enough
Elon Musk compares George Soros to Magneto, the supervillain from the Marvel Comics series.
Warren Buffett Sells TSMC Shares Over Concerns About Taiwan's Stability
New Study Finds That Secondary Bacterial Pneumonia Is a Major Cause of Death in COVID-19 Patients Who Require Ventilator Assistance
King Charles III being crowned.
'Godfather Of AI' Geoffrey Hinton Quits Google To Warn Of The Tech's Dangers
A Real woman
Vermont Man Charged with Stalking After Secretly Tracking Woman with Apple AirTag
Elon Musk Statements About Tesla Autopilot Could Be 'Deepfakes,' Lawyers Claim. Judge Evette Pennypacker Does Not Understand How Far and Advanced This Technology Became
Ukraine More Prepared for Counterattack as Reinforcements Arrive
UK Prime Minister Rishi Sunak and Italian Prime Minister Giorgia Meloni Discuss Migration, Defence, and Ukraine
Tucker Carlson is back, soon!
AT&T's Successful Test of Satellite-Based Phone Call Raises Possibility of Widespread Coverage
CNN: "Joe Biden is asking for four more years — when 74% of Americans think the country is heading the wrong way“
Turkish President Recep Tayyip Erdogan Cuts Short Live TV Interview Due to Health Issue
US Congresswoman threaten Twitter Files journalist with arrest
Pulitzer Prize-winning journalist Seymour Hersh slams New York Times' pro-government stance and treatment of sources
Enough is enough: it's time to end the war in Ukraine. While Russia may be to blame for starting it, Russia is not the one refusing to stop it
Fox News Settles their case with Dominion Voting Systems for a staggering $787.5 MILLION
The land of the free violence